Can dietary factors influence prostatic disease?

BJU International

Volumn 84, Issue 5, 1999, Pages 549-554

  Morton, M S ^a   Turkes, A ^a   Denis, L ^b   Griffiths, K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Oncology Centre of Antwerp   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; DNA TOPOISOMERASE; ESTROGEN; FINASTERIDE; FLAVONOID; ISOFLAVONOID; LIGNAN; PROTEIN KINASE; STEROID 5ALPHA REDUCTASE;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; BODY FLUID; CANCER INCIDENCE; CARCINOGENESIS; DIETARY INTAKE; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; REVIEW;

ANTIOXIDANTS; AROMATASE INHIBITORS; DIET; DNA TOPOISOMERASES, TYPE I; ESTROGENS; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; OXIDOREDUCTASES; PROSTATIC DISEASES; PROTEIN-TYROSINE KINASES;

EID: 0032818920     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1999.00270.x     Document Type: Review

References (40)

1. 1 Silverberg E, Boring CC, Squires TS. Cancer statistics. Cancer J Clin 1990; 40: 9-26
2. 2 Boyle P. Evolution of an epidemic of unknown origin. In Denis L ed. European School of Oncology Monograph. Prostate Cancer 2000. Heidelberg: Springer Verlag, 1994: 5-11
3. 3 Boyle P, Napalkov P, Barry MJ et al. Epidemiology and natural history of prostatic cancer. In Murphy G, Griffiths K, Denis L et al. eds. First International Consultation on Prostatic Cancer. Paris: SCI, 1997: 1-29
4. 4 Parkin DM, Muir CS, Whelan S, Gao YT, Ferlay J. Powell J. Cancer Incidence in Five Continents, Vol. VI. Lyon: IARC Scientific Publication, 1992: 120
5. 5 Breslow N, Chan CE, Dhom G et al. Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer 1977; 20: 680-8
6. 6 Shimizu H, Ropp RK, Bernstein L, Yatani R, Henderson BE, Mack TH. Cancers of the breast and prostate among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63: 963-6
7. 7 Griffiths K, Adlercreutz H, Boyle P, Denis L, Nicholson RI, Morton MS eds. Nutrition and Cancer. Oxford: Isis Medical Media, 1996
8. 8 Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest 1990; 50: 3-23
9. 9 Bradbury RB, White DC. Oestrogens and related substances in plants. Vitam Horm 1954; 12: 207-33
10. 10 Setchell KDR, Adlercreutz H. Mammalian lignans and phytooestrogens. Recent studies on their formation, metabolism and biological role in health and disease. In Rowland IR ed. Role of Gut Flora in Toxicity and Cancer. London: Academic Press, 1988; 315-45
11. 11 Thompson LU, Robb P, Serraino M, Cheung F. Mammalian lignan production from various foods. Nutr Cancer 1991; 16: 43-52
12. 12 Miksicek RJ. Estrogenic flavonoids: structural requirements for biological activity. Pro Soc Exp Biol Med 1995; 208: 440-50
13. 13 Morand C, Crespy V, Manach C, Besson C, Demigne C, Remesy C. Plama metabolites of quercetin and their antioxidant properties. Am J Physiol 1998; 275: 212-9
14. 14 Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993; 342: 1209-10
15. 15 Adlercreutz H, Fotsis T, Bannwart C et al. Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem 1986; 25: 791-7
16. 16 Kuiper GG, Lemmen JG, Carlsson B et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139: 4252-63
17. 17 Griffiths K, Akaza H, Eaton CL et al. Regulation of Prostatic growth. In Cockett ATK, Khoury S, Aso Y et al. eds. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH) Paris. Paris: SCI, 1993: 49-75
18. 18 Evans BAJ, Griffiths K, Morton M. Inhibition of 5α-reductase and 17β-hydroxysteroid dehydrogenase in genital skin libroblasts by dietary lignans and isoflavonoids. J Endocrinol 1995; 147: 295-302
19. 19 Makela S, Poutanen M, Kostian ML et al. Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells. Proc Soc Exp Biol Med 1998; 217: 310-6
20. 20 Ross RK, Bernstein L, Lobo RA et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887-9
21. 21 Rittmaster RS. Finasteride. New Eng J Med 1994; 330: 120-5
22. 22 Vermeulen A, Deslypere JP, Meirleir K. A new look to the andropause: altered function of the gonadotrophs. J Steroid Biochem 1989; 32: 163-5
23. 23 Adlercreutz H, Bannwart C, Wahala K et al. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Molec Biol 1993; 44: 147-53
24. 24 Pelissero C, Lenczowski MJ, Chinzi D, Davail-Ciusset B, Sumpter JP, Fostier A. Effects of flavonoids on aromatase activity, an in vitro study. J Steroid Biochem Mol Biol 1996; 57: 215-23
25. 25 Hunter T, Cooper JA. Protein tyrosine kinases. Ann Rev Biochem 1985; 54: 897-930
26. 26 Kenyon GL, Garcia GA. Design of kinase inhibitors. Med Res Rev 1987; 7: 389-416
27. 27 Akiyama T, Ishida J. Nakagawa S et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592-5
28. 28 Kuo ML, Lin JK, Huang TS, Yang NC. Reversion of the transformed phenotypes of v-H-ras NIH3T3 cells by flavonoids through attenuating the content of phosphotyrosine. Cancer Lett 1994; 87: 91-7
29. 29 Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 1993; 4: 535-43
30. 30 McCabe M Jr, Orrenius S. Genistein induces apoptosis in immature human thymocytes by inhibiting topoisomerase-II. Biochem Biophys Res Comm 1993; 194: 944-50
31. 31 Constantinou A, Mehta R, Runyan C, Rao K, Vaughan A, Moon R. Flavonoids as DNA topoisomerase antagonists and poisons. Structure-activity relationships. J Nat Prod 1995; 58: 217-25
32. 32 Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61
33. 33 Fotsis T, Pepper M, Adlercreutz H et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci 1993; 90: 2690-4
34. 34 Fotsis T, Pepper MS, Aktas E et al. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 1997; 57: 2916-21
35. 35 Rice-Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Rad Res 1995; 22: 375-83
36. 36 Mangiapane H, Thomson J, Salter A, Brown S, Bell GD, White DA. The inhibition of the oxidation of low density lipoprotein by (+)-catechin, a naturally occurring flavonoid. Biochem Parmacol 1992; 43: 445-50
37. 37 Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutrition Cancer 1994; 21: 113-30
38. 38 Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993; 22: 335-45
39. 39 Kimira M, Arai Y, Shimoi K, Watanabe S. Japanese intake of flavonoids and isoflavonoids from food. J Epidemiol 1998; 8: 168-75
40. 40 Fukutake M, Takahashi M, Ishida K, Kawamura H, Sugimura T, Wakabayashi K. Quantification of genistein and genistin in soybeans and soybean products. Food Chem Toxicol 1996; 34: 457-61